Microfluidic iPSC Reprogramming With Automated Clone Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells (iPSCs) are time-consuming and labor-intensive, with challenges in accurately identifying fully-reprogrammed cells and efficiently processing patient-specific cells for therapeutic applications.
Innovation Solution
A microfluidic system that automates the processing of biological samples to isolate, expand, reprogram, and differentiate cells, enabling efficient generation of patient-specific iPSCs and their derivatives for treatment, using integrated microfluidic units and computer-controlled processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual methods are used to identify and pick iPSC clones, then operator skill and time are required, but the process is time-consuming and labor-intensive with difficulty in accurately identifying fully-reprogrammed cells
Solution Approach 1:
The patent replaces manual mechanical picking with an automated microfluidic system that uses digital imaging and automated cell manipulation. The system captures images of cell colonies, automatically identifies iPSC clones based on morphological criteria, and uses a microfluidic picker to isolate selected colonies without manual intervention, thereby eliminating the time-consuming and labor-intensive manual process while improving identification accuracy.
Solution Approach 2:
The system enables self-service by incorporating automated image analysis and colony identification algorithms that independently assess cell morphology and select iPSC clones without requiring operator expertise. The microfluidic device autonomously performs colony picking based on automated criteria, allowing the system to serve itself rather than relying on external manual operation.
2Manufacturing precision
If complex control machinery is built into microfluidic chips to achieve precise transfer and mixing, then control precision is improved, but device complexity increases with multiple components
Solution Approach 1:
The patent extracts the complex control machinery from the microfluidic chip itself and relocates it to external equipment. The microfluidic device contains only simple channels and wells for cell manipulation, while precise control of fluid flow, mixing, and timing is achieved through externally controlled dispensing and pumping systems, thereby simplifying the chip design while maintaining manufacturing precision.
Solution Approach 2:
The system employs universal external control mechanisms that can manage multiple microfluidic devices simultaneously. A single external controller handles dispensing, mixing, and cell manipulation across various chips, reducing the need for dedicated complex control machinery in each individual device while maintaining precise operational control.
Data Source
AI summary
This invention concerns an integrated microfluidic system that utilizes microfluidic chip technology to receive a patient sample including cells, expand the cells, reprogram the expanded cells and then store the reprogrammed cells in a microfluidic chip. These microfluidic chips with stored reprogrammed cells may then be used in scenarios of genetic differentiation into specific cell types. Overall this system and workflow is suitable as a hospital based device that will allow the generation of iPSCs from every patient for downstream diagnostic or therapeutic use.